CO6160288A2 - Composiciones farmaceuticas que comprenden nilotinib o su sal - Google Patents

Composiciones farmaceuticas que comprenden nilotinib o su sal

Info

Publication number
CO6160288A2
CO6160288A2 CO09041795A CO09041795A CO6160288A2 CO 6160288 A2 CO6160288 A2 CO 6160288A2 CO 09041795 A CO09041795 A CO 09041795A CO 09041795 A CO09041795 A CO 09041795A CO 6160288 A2 CO6160288 A2 CO 6160288A2
Authority
CO
Colombia
Prior art keywords
lower alkyl
substituted
mono
zero
amino
Prior art date
Application number
CO09041795A
Other languages
English (en)
Inventor
Nathalie Breneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6160288(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6160288A2 publication Critical patent/CO6160288A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

1.- Una composición farmacéutica, en la forma de una cápsula, la cual comprende: un gránulo que comprende un compuesto terapéutico en una mezcla íntima con cuando menos un excipiente farmacéuticamente aceptable, en donde este compuesto terapéutico es una pirimidiI-amino-benzamida de la fórmula I:en donde: R1 representa hidrógeno, alquilo inferior, alcoxilo inferior- alquilo inferior, aciloxi-alquilo inferior, carboxi-alquilo interior, alcoxilo inferior-carbonil-alquilo inferior, o fenil-alquilo inferior; R2 representa hidrógeno, alquilo inferior, opcionalmente sustituido por uno o más radicales idénticos o diferentes R3, cicloalquilo, benzocicloalquilo, heterociclilo, un grupo arilo, o un grupo heteroarilo mono- o bi-cíclico que comprende cero, uno, dos, o tres átomos de nitrógeno del anillo, y cero o un átomo de oxígeno, y cero o un átomo de azufre, cuyos grupos en cada caso están insustituidos o mono- o poli-sustituidos; y R3 representa hidroxilo, alcoxilo inferior, aciloxilo, carboxilo, alcoxilo inferior-carbonilo, carbamoílo, carbamoílo N-mono- o N,N-di-sustituido, amino, amino mono- o di-sustituido, cicloalquilo, heterociclilo, un grupo arilo, o un grupo heteroarilo mono- o bi-cíclico que comprende cero, uno, dos, o tres átomos de nitrógeno del anillo, y cero o un átomo de oxígeno, y cero o un átomo de azufre, cuyos grupos en cada caso están insustituidos o mono- o poli-sustituidos; o en donde R1 y R2 representan juntos alquileno con cuatro, cinco, o seis átomos de carbono, opcionalmente mono- o di-sustituido por alquilo inferior, cicloalquilo, heterociclilo, fenilo, hidroxilo, alcoxilo inferior, amino, amino mono- o di-sustituido, oxo, piridilo, pirazinilo, o pirimidinilo; benzalquileno con cuatro o cinco átomos de carbono; oxa-alquileno con un átomo de oxígeno y tres o cuatro átomos de carbono; o aza-alquileno con un átomo de nitrógeno y tres o cuatro átomos de carbono, en donde el nitrógeno está insustituido o sustituido por alquilo inferior, fenil-alquilo inferior, alcoxilo inferior-carbonil-alquilo inferior, carboxi-alquilo inferior, carbamoil-alquilo inferior, carbamoil-alquilo inferior N-mono- o N,N-di-sustituido, cicloalquilo, alcoxilo inferior-carbonilo, carboxilo, fenilo, fenilo sustituido, piridinilo, pirimidinilo, o pirazinilo; R4 representa hidrógeno, alquilo inferior, o halógeno; en donde el prefijo "inferior" denota un radical que tiene hasta e incluyendo un máximo de siete átomos de carbono, siendo los radicales en cuestión lineales o ramificados con ramificación individual o múltiple, o un N-óxido, o una sal farmacéuticamente aceptable de este compuesto de pirimidil-amino-benzamida de la fórmula I.
CO09041795A 2006-09-27 2009-04-24 Composiciones farmaceuticas que comprenden nilotinib o su sal CO6160288A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number Publication Date
CO6160288A2 true CO6160288A2 (es) 2010-05-20

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09041795A CO6160288A2 (es) 2006-09-27 2009-04-24 Composiciones farmaceuticas que comprenden nilotinib o su sal

Country Status (35)

Country Link
US (2) US8293756B2 (es)
EP (4) EP1923053A1 (es)
JP (2) JP5567340B2 (es)
KR (2) KR20090076931A (es)
CN (2) CN101516344A (es)
AR (1) AR062980A1 (es)
AU (1) AU2007301977B2 (es)
BR (1) BRPI0719438B1 (es)
CA (1) CA2662571C (es)
CL (1) CL2007002766A1 (es)
CO (1) CO6160288A2 (es)
CY (2) CY1117021T1 (es)
DK (2) DK2068839T3 (es)
ES (3) ES2556625T5 (es)
FI (2) FI3984528T3 (es)
HK (1) HK1133193A1 (es)
HR (2) HRP20230753T3 (es)
HU (2) HUE063083T2 (es)
IL (1) IL197496A (es)
JO (1) JO3757B1 (es)
LT (1) LT3984528T (es)
MA (1) MA30807B1 (es)
MX (1) MX2009003184A (es)
MY (1) MY148237A (es)
NO (2) NO347404B1 (es)
NZ (1) NZ575317A (es)
PE (2) PE20120626A1 (es)
PL (2) PL3984528T3 (es)
PT (2) PT3984528T (es)
RU (1) RU2469707C2 (es)
SI (2) SI2068839T2 (es)
TN (1) TN2009000093A1 (es)
TW (3) TWI428333B (es)
WO (1) WO2008037716A2 (es)
ZA (1) ZA200901511B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CA2775400A1 (en) 2009-09-28 2011-03-31 Medizinische Universitat Wien New use of pdgfrbeta inhibitors
US20120202836A1 (en) 2009-10-23 2012-08-09 Tomasz Szczudlo Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (es) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
AU2012328979B2 (en) 2011-10-28 2016-04-21 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140093230A (ko) * 2011-11-14 2014-07-25 노파르티스 아게 즉시 방출 4-메틸-3-[[4-(3-피리디닐)-2-피리미디닐]아미노]-n-[5-(4-메틸-1h-이미다졸-1-일)-3-(트리플루오로메틸)페닐] 벤즈아미드 제제
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
JP2015522070A (ja) 2012-07-11 2015-08-03 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
US9682081B2 (en) 2013-04-25 2017-06-20 Sun Pharmaceutical Industries Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
PL3189045T3 (pl) 2014-08-11 2022-04-04 Sun Pharmaceutical Industries Limited Nowe sole nilotynibu i jego polimorfy
WO2016033304A1 (en) * 2014-08-28 2016-03-03 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
WO2017158625A1 (en) * 2016-03-17 2017-09-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
WO2024142002A1 (en) 2022-12-29 2024-07-04 Renata Pharmaceuticals (Ireland) Limited Pharmaceutical suspension of nilotinib
WO2024194718A1 (en) * 2023-03-22 2024-09-26 Unichem Laboratories Limited A stable pharmaceutical composition and process for preparing thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
EP0925294B3 (en) 1996-07-24 2018-07-04 Celgene Corporation Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
ES2435816T3 (es) 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
CA2362816C (en) * 1999-12-08 2007-02-06 Pharmacia Corporation Valdecoxib compositions
KR20020071931A (ko) 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
BR0312445A (pt) * 2002-06-07 2005-05-10 Ranbaxy Lab Ltd Sistemas multiunitários para disponibilização de fármaco de liberação modificada
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ATE536930T1 (de) * 2002-11-26 2011-12-15 Univ Gent Verfahren und vorrichtung zur feuchtgranulierung von pulver
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
EP1776102A1 (en) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
AU2005290583A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particles-containing composition and manufacturing method therefor
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
RU2404776C2 (ru) * 2005-01-28 2010-11-27 Новартис Аг ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2
KR20070106036A (ko) * 2005-02-25 2007-10-31 노파르티스 아게 Bcr-abl 및 raf 억제제의 제약 조합물
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CA2660086C (en) * 2006-08-16 2014-09-16 Novartis Ag Method of making solid dispersions of highly crystalline therapeutic compounds
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
SI2068839T2 (sl) 2023-01-31
HK1133193A1 (en) 2010-03-19
NO346639B1 (no) 2022-11-07
HRP20151383T1 (hr) 2016-01-15
HUE028204T2 (en) 2016-12-28
JO3757B1 (ar) 2021-01-31
SI3984528T1 (sl) 2023-09-29
BRPI0719438B1 (pt) 2022-04-19
IL197496A (en) 2016-04-21
LT3984528T (lt) 2023-08-10
FI3984528T3 (fi) 2023-07-27
US20130023549A1 (en) 2013-01-24
ES2951547T3 (es) 2023-10-23
CY1117021T1 (el) 2017-04-05
HUE063083T2 (hu) 2023-12-28
AR062980A1 (es) 2008-12-17
IL197496A0 (en) 2009-12-24
MX2009003184A (es) 2009-04-03
CY1126116T1 (el) 2023-11-15
US8501760B2 (en) 2013-08-06
BRPI0719438A2 (pt) 2013-12-10
DK3984528T3 (da) 2023-07-31
PL2068839T5 (pl) 2023-01-30
TW200821298A (en) 2008-05-16
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
PT2068839E (pt) 2015-12-30
KR101598747B1 (ko) 2016-03-02
TW201418245A (zh) 2014-05-16
US20100087463A1 (en) 2010-04-08
RU2009115782A (ru) 2010-11-10
CA2662571C (en) 2016-09-27
HRP20230753T3 (hr) 2023-10-27
EP1923053A1 (en) 2008-05-21
AU2007301977A1 (en) 2008-04-03
PT3984528T (pt) 2023-08-07
NO20220946A1 (no) 2009-04-24
CN104306350A (zh) 2015-01-28
JP2010504942A (ja) 2010-02-18
NZ575317A (en) 2011-12-22
NO347404B1 (no) 2023-10-16
TN2009000093A1 (en) 2010-08-19
ES2957912T3 (es) 2024-01-29
EP3984528B1 (en) 2023-07-05
EP2068839B2 (en) 2022-10-12
WO2008037716A3 (en) 2008-07-17
KR20140121903A (ko) 2014-10-16
MA30807B1 (fr) 2009-10-01
PL3984528T3 (pl) 2023-08-28
CL2007002766A1 (es) 2008-08-08
EP3009128B1 (en) 2023-07-05
EP2068839A2 (en) 2009-06-17
EP3984528A1 (en) 2022-04-20
ES2556625T5 (es) 2023-03-02
MY148237A (en) 2013-03-29
PL2068839T3 (pl) 2016-06-30
CN101516344A (zh) 2009-08-26
TWI540128B (zh) 2016-07-01
ZA200901511B (en) 2010-02-24
CA2662571A1 (en) 2008-04-03
HRP20151383T4 (hr) 2023-03-03
ES2556625T3 (es) 2016-01-19
SI2068839T1 (sl) 2016-02-29
NO20091501L (no) 2009-04-24
DK2068839T3 (da) 2016-01-11
JP2014065715A (ja) 2014-04-17
TWI428333B (zh) 2014-03-01
RU2469707C2 (ru) 2012-12-20
US8293756B2 (en) 2012-10-23
PE20081379A1 (es) 2008-11-27
PE20120626A1 (es) 2012-06-07
KR20090076931A (ko) 2009-07-13
JP5567340B2 (ja) 2014-08-06
AU2007301977B2 (en) 2011-09-08
EP2068839B1 (en) 2015-09-23
EP3009128A1 (en) 2016-04-20
FI2068839T4 (fi) 2023-01-31

Similar Documents

Publication Publication Date Title
CO6160288A2 (es) Composiciones farmaceuticas que comprenden nilotinib o su sal
AR040390A1 (es) Inhibidores de quinasas de tirosina
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
AR057131A1 (es) Derivados de purina como inmunomodulador
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
AR074822A1 (es) Compuestos heterociclicos de pirazina utiles como inhibidores de proteinquinasas atr, composiciones farmaceuticas que los comprenden y uso de los mismos en el tratamiento del cancer
AR032467A1 (es) Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
WO2015157128A1 (en) Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
AR053845A1 (es) 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR055212A1 (es) Compuestos heterociclicos como bloqueantes del canal ionico p2x7
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR087841A1 (es) Derivados de tetrahidrotriazolopirimidina
AR030230A1 (es) Derivados de acilfenilurea, procedimiento para su preparacion y su empleo en la preparacion de medicamentos
AR042052A1 (es) Diaminotriazoles utiles como inhibidores de proteinquinasas
RU2008150383A (ru) Соединение с-фенилглицитола для лечения диабета
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR086095A1 (es) Derivados de nucleosidos 2’-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
RU2015106605A (ru) Соединения замещенных пиразолонов и способы использования
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.